Peritoneal Mesothelioma

HIPEC plus cytoreductive surgery is the standard of care for peritoneal mesothelioma. Eligibility, the day-of procedure, and 90-day recovery — explained.

Up to 25% of mesothelioma patients receive an incorrect initial diagnosis. Learn the most common misdiagnoses, how pathology errors happen, and 5 steps to confirm your diagnosis.

Peritoneal mesothelioma treatment 2026: CRS-HIPEC surgery pushes 5-year survival to 59%, median 4-8 years. Plus emerging immunotherapy and PIPAC options.

CRS-HIPEC (cytoreductive surgery + hyperthermic chemotherapy) achieves 53-month median survival and 47% five-year survival for peritoneal mesothelioma patients. Learn candidacy, outcomes, and leading treatment centers.